CORT

Corcept Therapeutics Stock Analysis

AI Rating

Low
  • Quality9/10
  • Growth↓ 0/10
  • Value↓ 1/10
Corcept Therapeutics sales and earnings growth
CORT Growth
Low
  • Revenue Y/Y↑ 11.29%
  • EPS Y/Y↓ -63.78%
  • FCF Y/Y↓ -32.34%
Corcept Therapeutics gross and profit margin trends
CORT Profitability
Good
  • Gross margin ↑ 98.30%
  • EPS margin↓ 6.10%
  • ROIC 5Y↓ 22.58%
Corcept Therapeutics net debt vs free cash flow
CORT Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -0.4

Corcept Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks